Yahoo Finance

Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder. The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on MNMD:

• AMD downgraded, Cisco upgraded: Wall Street’s top analyst calls

• Mind Medicine initiated with an Outperform at Evercore ISI

• Rising High: Innovative Industrial reports PharmaCann default

• Mind Medicine initiated with a Buy at Chardan

• Mind Medicine to be added to Nasdaq Biotechnology Index December 23.